Stockholders' Equity

3 Months Ended

Oct. 31, 2025

Equity [Abstract]

Stockholders' Equity

Stockholders’ Equity

Total stock-based compensation expense recognized in the three-month periods ended October 31, 2025 and October 31, 2024 for stock-based awards totaled $10,950 and $10,537, respectively.

Share Repurchase Program

As discussed in Note 16 to the Company’s Consolidated Financial Statements included in the Fiscal 2025 Form 10-K, on December 21, 2021, the Company’s Board of Directors authorized Company management to utilize up to $250,000 to repurchase shares of the Company’s common stock through December 21, 2024. On June 24, 2022, the Board authorized Company management to utilize up to an additional $448,321 to repurchase shares of the Company’s common stock through July 31, 2025.

On June 18, 2025, the Board retired the Company's existing share repurchase authorization which was set to expire on July 31, 2025 and authorized the Company's management to utilize up to $400,000 to purchase shares of the Company's common stock beginning on June 18, 2025 and extending through July 31, 2027. The June 18, 2025 authorization is the only active share repurchase authorization.

During the three-month period ended October 31, 2025, the Company purchased 50,235 shares of its common stock at various times in the open market, at a weighted-average price of $100.48 and held them as treasury shares at an aggregate purchase price of $5,047, all from the June 18, 2025 authorization. During the three-month period ended October 31, 2024, the Company did not purchase any shares of its common stock.

As of October 31, 2025, the remaining amount of the Company’s common stock that may be repurchased under the June 18, 2025 authorization expiring on July 31, 2027 is $374,253.